Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study

Table 5 Landmark analysis of MACE in ACS patients after PCI

Variable	MACE, %	Hazard ratio	95% CI	SEM	P value
≤ 30 months
Hypertension		1.047	1.014 to 1.080	0.016	0.005
PLT		1.006	1.001 to 1.011	0.003	0.012
FIB-L	10.9
FIB-M^a	26.3	3.798	1.508 to 9.564	0.471	0.005
FIB-H^a	27.7	4.405	1.587 to 12.227	0.521	0.004
31 months to maximum follow-up
Hypertension		1.002	1.001 to 1.003	0.001	< 0.001
Smoking		1.039	1.004 to 1.076	0.018	0.029
CRE		0.973	0.949 to 0.997	0.013	0.030
FIB-L	36
FIB-M^a	34	1.458	0.548 to 3.876	0.499	0.450
FIB-H^a	30.6	1.356	0.395 to 4.656	0.629	0.628

ACS acute coronary syndrome, PCI percutaneous coronary intervention, MACE major adverse cardiovascular events, PLT platelet, FIB fibrinogen, CRE creatinine, CI confidence interval, SEM standard error of measurement
^aCompared with FIB-L group

ISSN: 1475-2840